lobbying_activities: 3054717

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3054717	ac551ec4-8c32-48f5-a455-8727c7641269	Q3	PORT SIDE STRATEGIES, LLC	401105394	NEW VENTURE FUND	2023	third_quarter	PHA	Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S.2305 - Biosimilar Red Tape Elimination Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. H.R.4895 - Lowering Drug Costs for American Families Act - in support.	HOUSE OF REPRESENTATIVES,SENATE,White House Office			0	0	2023-10-17T21:07:22-04:00